Skip Navigation

Annick D. Van den Abbeele, MD, FACR


Radiology

Make an Appointment

Physician

  • Chief, Department of Imaging
  • Institute Physician
  • Associate Professor of Radiology, Harvard Medical School

Centers/Programs

Clinical Interests

  • Cancer imaging quantitative metrics
  • Molecular imaging
  • Monitoring of therapeutic response
  • Nuclear medicine
  • PET
  • Radiotherapy with unsealed sources
  • Sarcoma

Contact Information

  • Office Phone Number617-632-2595
  • Fax617-582-8574

Bio

Board Certification:

  • Nuclear Medicine, 1993

Fellowship:

  • Brigham and Women's Hospital/Harvard Medical School, Radiology & Nuclear Medicine
  • Vanderbilt University School of Medicine, Neonatology

Residency:

  • Joint Program in Nuclear Medicine, Harvard Medical School
  • University of Louvain, Pediatrics

Medical School:

  • Catholic University of Louvain

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston MA, 02215
Get Directions

Research

Suh CH, Shinagare AB, Westenfield AM, Ramaiya NH, Van den Abbeele AD, Kim KW. Yield of bone scintigraphy for the detection of metastatic disease in treatment-naive prostate cancer: a systematic review and meta-analysis. Clin Radiol. 2017 Sep 25.
View in: PubMed

Alabed YZ, Cheng SC, Mudge C, Sakellis C, Van den Abbeele AD, Campos SM, Jacene HA. Surveillance Imaging in Patients With Endometrial Cancer in First Remission. Curr Probl Diagn Radiol. 2017 Aug 24.
View in: PubMed

Shields AF, Jacobs P, Sznol M, Graham MM, Germain R, Lum L, Jaffee E, de Vries EGE, Nimmagadda S, Van den Abbeele AD, Leung D, Wu AM, Sharon E, Shankar LK. Immune Modulation Therapy and Imaging: Workshop Report. J Nucl Med. 2017 Aug 17.
View in: PubMed

Krajewski KM, Howard SA, Shinagare AB, Van den Abbeele AD, Fennessy FM. Cancer Imaging Fellowship Training: Utility and Added Value in the Modern Era. J Am Coll Radiol. 2017 Oct; 14(10):1345-1348.
View in: PubMed

McIntosh LJ, O'Neill AC, Bhanusupriya S, Matalon SA, Van den Abbeele AD, Ramaiya NH, Shinagare AB. Prognostic significance of supradiaphragmatic lymph nodes at initial presentation in patients with stage III high-grade serous ovarian cancer. Abdom Radiol (NY). 2017 Apr 20.
View in: PubMed

Shinagare AB, Suh CH, Kim KW, Somarouthu B, Van den Abbeele AD, Ramaiya NH. Ovarian Cancer: An Evidence-Based, Easy-to-Use Prediction Rule to Optimize the Use of Follow-up Chest CT. J Am Coll Radiol. 2017 Apr; 14(4):499-508.
View in: PubMed

O'Neill AF, Qin L, Wen PY, de Groot JF, Van den Abbeele AD, Yap JT. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol. 2016 Dec; 130(3):495-503.
View in: PubMed

O'Neill AC, Somarouthu B, Tirumani SH, Braschi-Amirfarzan M, Van den Abbeele AD, Ramaiya NH, Shinagare AB. Patterns and Prognostic Importance of Hepatic Involvement in Patients with Serous Ovarian Cancer: A Single-Institution Experience with 244 Patients. Radiology. 2017 Jan; 282(1):160-170.
View in: PubMed

Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016 Sep; 27(9):1794-9.
View in: PubMed

Van den Abbeele AD, Krajewski KM, Tirumani SH, Fennessy FM, DiPiro PJ, Nguyen QD, Harris GJ, Jacene HA, Lefever G, Ramaiya NH. Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center. J Am Coll Radiol. 2016 Apr; 13(4):365-71.
View in: PubMed

Tirumani SH, Sakellis C, Jacene H, Shinagare AB, Munshi NC, Ramaiya NH, Van den Abbeele AD. Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome. Clin Nucl Med. 2016 Jan; 41(1):e7-13.
View in: PubMed

Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35.
View in: PubMed

Alabed YZ, Aghayev A, Sakellis C, Van den Abbeele AD. Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT. Clin Nucl Med. 2015 Nov; 40(11):e528-9.
View in: PubMed

Buchbinder EI, Sosman JA, Lawrence DP, McDermott DF, Ramaiya NH, Van den Abbeele AD, Linette GP, Giobbie-Hurder A, Hodi FS. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Cancer. 2015 Nov 15; 121(22):4007-15.
View in: PubMed

Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). J Clin Oncol. 2015 Aug 20; 33(24):2623-31.
View in: PubMed

Howard SA, Krajewski KM, Weissman BN, Seltzer SE, Ramaiya NH, Van den Abbeele AD. Cancer Imaging Training in the 21st Century: An Overview of Where We Are, and Where We Need To Be. J Am Coll Radiol. 2015 Jul; 12(7):714-20.
View in: PubMed

Shinagare AB, O'Neill AC, Cheng S, Somarouthu B, Tirumani SH, Nishino M, Van den Abbeele AD, Ramaiya NH. Advanced High-Grade Serous Ovarian Cancer: Frequency and Timing of Thoracic Metastases and the Implications for Chest Imaging Follow-up. Radiology. 2015 Dec; 277(3):733-40.
View in: PubMed

McCall KC, Cheng SC, Huang Y, Kohl NE, Tupper T, Van den Abbeele AD, Zukotynski KA, Sweeney CJ. [(18)F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments. Transl Oncol. 2015 Jun; 8(3):147-53.
View in: PubMed

Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015 Mar-Apr; 35(2):424-37.
View in: PubMed

Zukotynski K, Yap JT, Giobbie-Hurder A, Weber J, Gonzalez R, Gajewski TF, O'Day S, Kim K, Hodi FS, Van den Abbeele AD. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30.
View in: PubMed

Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015 Apr; 13(2):113-23.
View in: PubMed

Krajewski KM, Franchetti Y, Nishino M, Fay AP, Ramaiya N, Van den Abbeele AD, Choueiri TK. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. Oncologist. 2014 May; 19(5):507-14.
View in: PubMed

Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott D. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014 Jul; 2(7):632-42.
View in: PubMed

Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2014 Apr 20; 32(12):1202-9.
View in: PubMed

Guo M, Yap JT, Van den Abbeele AD, Lin NU, Schwartzman A. Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology. Stat. 2014 Jan 01; 3(1):172-186.
View in: PubMed

O'Regan K, Breen M, Ramaiya N, Jagannathan J, DiPiro PJ, Hodi FS, Van den Abbeele AD. Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence. Cancer Imaging. 2013 Dec 30; 13(4):626-32.
View in: PubMed

Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, Choueiri TK. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer. 2014 Mar 01; 120(5):711-21.
View in: PubMed

Yeh ED, Jacene HA, Bellon JR, Nakhlis F, Birdwell RL, Georgian-Smith D, Giess CS, Hirshfield-Bartek J, Overmoyer B, Van den Abbeele AD. What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. Radiographics. 2013 Nov-Dec; 33(7):2003-17.
View in: PubMed

Pyo J, Won Kim K, Jacene HA, Sakellis CG, Brown JR, Van den Abbeele AD. End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res. 2013 Dec 01; 19(23):6566-77.
View in: PubMed

Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
View in: PubMed

Vinjamoori AH, Jagannathan JP, Shinagare AB, Taplin ME, Oh WK, Van den Abbeele AD, Ramaiya NH. Atypical metastases from prostate cancer: 10-year experience at a single institution. AJR Am J Roentgenol. 2012 Aug; 199(2):367-72.
View in: PubMed

George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012 Jul 01; 30(19):2401-7.
View in: PubMed

Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):e647-54.
View in: PubMed

Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012 May 17; 119(20):4597-607.
View in: PubMed

Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel BA. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med. 2012 Apr; 53(4):567-74.
View in: PubMed

Shinagare AB, Giardino AA, Jagannathan JP, Van den Abbeele AD, Ramaiya NH. Hereditary cancer syndromes: a radiologist's perspective. AJR Am J Roentgenol. 2011 Dec; 197(6):W1001-7.
View in: PubMed

Krajewski KM, Giardino AA, Zukotynski K, Van den Abbeele AD, Pedrosa I. Imaging in renal cell carcinoma. Hematol Oncol Clin North Am. 2011 Aug; 25(4):687-715.
View in: PubMed

Van Den Abbeele AD, Tanaka Y, Locascio T, Sakellis C, Heinrich MC, von Mehren M, Choy E, Tap WD, Manola J, Demetri GD, George S, Yap JT. Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx). J Clin Oncol. 2011 May 20; 29(15_suppl):10050.
View in: PubMed

Lin NU, Mayer IA, Najita JS, Hobday TJ, Falkson CI, Dees EC, Rimawi MF, Nanda R, Gelman RS, Josephs K, Richardson A, Flores L, Van Den Abbeele AD, Yap JT, Arteaga CL, Wolff AC, Krop IE, Winer EP. TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC). J Clin Oncol. 2011 May 20; 29(15_suppl):527.
View in: PubMed

Hodi FS, Friedlander PA, Atkins MB, McDermott DF, Lawrence DP, Ibrahim N, Wu X, Zhou J, Giobbie-Hurder A, Murphy G, Hollman T, Velazquez E, Russell S, Dipiro P, Yap JT, Van Den Abbeele AD. A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2011 May 20; 29(15_suppl):8511.
View in: PubMed

George S, von Mehren M, Heinrich MC, Wang Q, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Manola J, Yap JT, Van Den Abbeele AD, Solomon S, Fletcher JA, Demetri GD. A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). J Clin Oncol. 2011 May 20; 29(15_suppl):10007.
View in: PubMed

Urban T, Sadow CA, Cleary JM, Harris GJ, Van Den Abbeele AD. Impact of RECIST 1.1 modifications on clinical trial eligibility. J Clin Oncol. 2011 May 20; 29(15_suppl):e16555.
View in: PubMed

Shinagare AB, Fennessy FM, Ramaiya NH, Jagannathan JP, Taplin ME, Van den Abbeele AD. Urothelial cancers of the upper urinary tract: metastatic pattern and its correlation with tumor histopathology and location. J Comput Assist Tomogr. 2011 Mar-Apr; 35(2):217-22.
View in: PubMed

Shinagare AB, Guo M, Hatabu H, Krajewski KM, Andriole K, Van den Abbeele AD, DiPiro PJ, Nishino M. Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center. Cancer. 2011 Aug 15; 117(16):3860-6.
View in: PubMed

Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, Choueiri TK. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol. 2011 May; 59(5):856-62.
View in: PubMed

Nishino M, Jackman DM, Hatabu H, Jänne PA, Johnson BE, Van den Abbeele AD. Imaging of lung cancer in the era of molecular medicine. Acad Radiol. 2011 Apr; 18(4):424-36.
View in: PubMed

Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD. Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011 Jan; 196(1):117-22.
View in: PubMed

Hall MN, Jagannathan JP, Ramaiya NH, Shinagare AB, Van den Abbeele AD. Imaging of extraosseous myeloma: CT, PET/CT, and MRI features. AJR Am J Roentgenol. 2010 Nov; 195(5):1057-65.
View in: PubMed

Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jänne PA, Van den Abbeele AD, Johnson BE. CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol. 2011 Jan; 18(1):54-62.
View in: PubMed

Shinagare AB, Jagannathan JP, Ramaiya NH, Hall MN, Van den Abbeele AD. Adult extragonadal germ cell tumors. AJR Am J Roentgenol. 2010 Oct; 195(4):W274-80.
View in: PubMed

Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010 Sep; 195(3):W221-8.
View in: PubMed

Lee AI, Zuckerman DS, Van den Abbeele AD, Aquino SL, Crowley D, Toomey C, Lacasce AS, Feng Y, Neuberg DS, Hochberg EP. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer. 2010 Aug 15; 116(16):3835-42.
View in: PubMed

Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010 Aug; 195(2):281-9.
View in: PubMed

Kuppens S, Bossaert G, Buntinx W, Molleman C, Van den Abbeele A, Maes B. Factorial validity of the Supports Intensity Scale (SIS). Am J Intellect Dev Disabil. 2010 Jul; 115(4):327-39.
View in: PubMed

Souza FF, Fennessy FM, Yang Q, van den Abbeele AD. Case report. PET/CT appearance of desmoid tumour of the chest wall. Br J Radiol. 2010 Feb; 83(986):e39-42.
View in: PubMed

Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009 Sep 15; 15(18):5902-9.
View in: PubMed

Souza FF, Otero HJ, Erturk M, Rybicki FJ, Ramaiya N, Van den Abbeele AD, Di Salvo DN. Venous thrombosis in an outpatient oncologic center: distribution, type, and comorbidities. Ultrasound Q. 2009 Sep; 25(3):145-50.
View in: PubMed

Otero HJ, Jagannathan JP, Prevedello LM, Johnston CJ, Ramaiya NH, Van den Abbeele AD, DiPiro PJ. CT and PET/CT findings of T-cell lymphoma. AJR Am J Roentgenol. 2009 Aug; 193(2):349-58.
View in: PubMed

Otero HJ, Yap JT, Patak MA, Erturk SM, Israel DA, Johnston CJ, Sakellis C, Rybicki FJ, Van den Abbeele AD, Ros PR. Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial. AJR Am J Roentgenol. 2009 Aug; 193(2):326-32.
View in: PubMed

Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, Siena S, Picus J, Butrynski JE, Schlemmer M, Heinrich MC, Demetri GD. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer. 2009 Jul; 52(7):767-71.
View in: PubMed

Sher DJ, Mauch PM, Van Den Abbeele A, LaCasce AS, Czerminski J, Ng AK. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol. 2009 Nov; 20(11):1848-53.
View in: PubMed

Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot Barnes A, Yap JT, Godwin AK, Blevins M, Eisenberg B, Siegel BA. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate (IM) for primary and recurrent operable malignant GIST: Imaging findings and correlation with genotype and GLUT4 expression. J Clin Oncol. 2009 May 20; 27(15_suppl):10552.
View in: PubMed

George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3154-60.
View in: PubMed

Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ. Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res. 2009 Mar 15; 15(6):1891-7.
View in: PubMed

Ertuk M, Van den Abbeele AD. Infrequent Tumors of the Gastrointestinal Tract Including Gastrointestinal Stromal Tumor (GIST). PET Clin. 2008 Apr; 3(2):207-15.
View in: PubMed

Van den Abbeele AD, Ertuk M. FDG-PET to Measure Response to Targeted Therapy: The Example of Gastrointestinal Stromal Tumor and Imatinib Mesylate (Gleevec). PET Clin. 2008 Jan; 3(1):77-87.
View in: PubMed

Sheehy N, Kulke MH, Van den Abbeele AD. F-18 FDG PET/CT in the diagnosis and management of a pericardiac paraganglioma. Clin Nucl Med. 2008 Aug; 33(8):545-6.
View in: PubMed

Erturk SM, Van den Abbeele AD. Role of PET/CT scanning in initial and post-treatment assessment of Hodgkin disease. J Natl Compr Canc Netw. 2008 Jul; 6(6):623-32.
View in: PubMed

Wagner AJ, Morgan JA, Chugh R, Rosen LS, George S, Gordon MS, Devine CM, Van den Abbeele AD, Grayzel D, Demetri GD. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial. J Clin Oncol. 2008 May 20; 26(15_suppl):10503.
View in: PubMed

Van den Abbeele AD, Yap JT, Rastarhuyeva I, Akhurst T, Keohan ML, George S, Bhuchar G, Morgan JA, Demetri GD, Maki RG. Early metabolic response to continuous daily dosing of sunitinib in soft tissue sarcomas (STS) other than GIST using FDG- PET. J Clin Oncol. 2008 May 20; 26(15_suppl):10529.
View in: PubMed

Oliveira GR, Zondervan RL, Van Den Abbeele AD, Barish MA, Urban T, Braschi M, Frenkel V, Hanlon WB, Harisinghani MG, Harris GJ. The impact of large lesions on the RECIST assessment criteria. J Clin Oncol. 2008 May 20; 26(15_suppl):17560.
View in: PubMed

Zondervan RL, Van den Abbeele AD, Barish MA, Urban T, Oliveira GR, Braschi M, Hanlon WB, Frenkel V, Harris GJ. Tumor imaging metrics core: A centralized service for standardized tumor measurements at a multi-institutional collaborative cancer center. J Clin Oncol. 2008 May 20; 26(15_suppl):20571.
View in: PubMed

Ross RW, Manola J, Oh WK, Ryan C, Kim J, Rastarhuyeva I, Yap JT, Van Den Abbeele AD, Kantoff PW, Taplin M. Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. J Clin Oncol. 2008 May 20; 26(15_suppl):5069.
View in: PubMed

Friedberg J, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher D, Szot A, Van Den Abbeele A, Freedman A. Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. Leuk Lymphoma. 2008 May; 49(5):902-9.
View in: PubMed

Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12):1993-9.
View in: PubMed

Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008 Apr 20; 26(12):2046-51.
View in: PubMed

Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr 15; 14(8):2387-95.
View in: PubMed

Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF, Syngal S, Garber JE. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA. 2008 Mar 19; 299(11):1315-9.
View in: PubMed

Van den Abbeele AD. The lessons of GIST--PET and PET/CT: a new paradigm for imaging. Oncologist. 2008; 13 Suppl 2:8-13.
View in: PubMed

Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007 Dec 15; 370(9604):2011-9.
View in: PubMed

Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD, Van den Abbeele AD. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol. 2007 Dec; 189(6):W324-30.
View in: PubMed

El Fakhri G, Santos PA, Badawi RD, Holdsworth CH, Van Den Abbeele AD, Kijewski MF. Impact of acquisition geometry, image processing, and patient size on lesion detection in whole-body 18F-FDG PET. J Nucl Med. 2007 Dec; 48(12):1951-60.
View in: PubMed

Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res. 2007 Oct 15; 13(20):6175-81.
View in: PubMed

Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, Silverman SG, Van den Abbeele AD, van Sonnenberg E, Demetri GD. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5398-405.
View in: PubMed

Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007 Jul; 5 Suppl 2:S1-29; quiz S30.
View in: PubMed

Jagannathan J.; Van den Abbeele A.D. Dana-Farber Cancer Institute, Boston, MA. Malignant Melanoma - Not Just Skin Deep!. American Journal of Roentgenology(AJR). 2007; 188(5):E140-A115.
View in: PubMed

Khosa F.; Ramaiya N.; Johnston C.; Disalvo D.; Jagannathan J.; Van den Abbeele A.D. Dana-Farber Cancer Institute, Boston, MA. Imaging of Venous Thrombosis in Oncologic Patients. American Journal of Roentgenology(AJR). 2007; 188(5):E136-A115.
View in: PubMed

Jagannathan J.; Van den Abbeele A.D. Dana-Farber Cancer Institute, Boston, MA. Missed Metastases-Causes and Clinical Relevance. American Journal of Roentgenology(AJR). 2007; 188(5):E145-A115.
View in: PubMed

L. Syrkin, D. J. de Vries, G. Lefever, T. Locascio, Y. Kuzuhara, A. D. Van den Abbeele, J. T. Yap, Nuclear Medicine/PET, Dana-Farber Cancer Institute, Boston, Massachusetts.(333352). Deveolpment of a PET/CT database of patient information and scanning parameters. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):199P/701.
View in: PubMed

G. Lefever, E. Andersen, J. T. Yap, A. D. Van den Abbeele, R. Tetrault; 1. Nucleare Medicine; 2. Environmental Health and Safety, Dana-Farber Cancer Institute, Boston, Massachusetts.(335244). Practical methods to minimize occupational radiation exposures in PET and nuclear medicine. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):452 p/2024.
View in: PubMed

T. Locascio, Y. Kuzuhara, L. Syrkin, D. J. de Vries, G. Lefever, A. D. Van den Abbbeele, J. T. Yap, Division of Nuclear Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.(334084). PET/CT quality assurance in clinical trials and good clinical practice. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):448P/2012.
View in: PubMed

N. Sheehy, I. A. David, A. D. Van den Abbeele, Radiology, Dana-Farber Cancer Institute, Boston, Massachusetts.(333139). Diagnosis of venous obstruction and thrombosis by radionuclinde venography in patients with central venous catheters. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):212P/1019.
View in: PubMed

Ji H.; Fennessyu F.; Van den Abbeele A.; Ros P. Department of Radiology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Lymphoma: Differentiation of Lymphoma from Other Conditions. American Journal of Roentgenology(AJR). 2007; 188(5):A125.
View in: PubMed

A. D. Van den Abbeele, J. T. Yap, D. S. Grayzel, J. Walker, G. D. Demetri; Dana-Farber Cancer Institute, Boston, MA; Infinity Pharmaceuticals Inc., Cambridge, MA. Inhibition and flare patterns of metabolic response to the heat shock protein 90(Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy. Journal of Clinical Oncology (JCO). 2007; 25(18S Part 1 of 2):145s/3530.
View in: PubMed

G. D. Demetri, S. George, J. A. Morgan, A. Wagner, M. T. Quigley, K. Polson, J. Pokela, A. Van den Abbeele, J. Adams, D. Grayzel; Dana-Farber Cancer Institute, Boston, MA; Infinity Pharmaceuticals, Cambridge, MA. Inhibition of the heat Shock Protein 90(Hsp90) chaperone with the novel agent PIP-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase 1 trial. Journal of Clinical Oncology (JCO). 2007; 25(18S Part 1 of 2):551s/10024.
View in: PubMed

Ji H.; Khosa F.; Van den Abbeele A. Department of Radiology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School., Boston, MA. Primary Malignant Neoplasms Mimicking Peritoneal Carcinomatosos: CT, MRI, and 18F FDG PET/CT Findings. American Journal of Roentgenology(AJR). 2007; 188(5):E207-A125-A140.
View in: PubMed

Sheehy N.P.; Israel D.; Ramaiya N.; Van den Abbeele A.D. Dana-Farber Cancer Institute, Boston, MA. 18FDG-PET/CT in Soft Tissue Sarcoma: Looking Beyond GIST. American Journal of Roentgenology(AJR). 2007; 188(5):E429-A191-A195.
View in: PubMed

Johnston C.; Ramaiya N.; Khosa F.; Van den Abbeele A. Dana-Farber Cancer Institute, Boston, MA. Radiological Response and Toxicity of the New Targeted Molecular Therapies for Cancer-What the Radiologist Needs to Know. American Journal of Roentgenology(AJR). 2007; 188(5):E419 A191-A195.
View in: PubMed

Sheehy N, Fennessy F, Van den Abbeele A D. The Utility of 18F-FDG-PET in the Diagnosis and Management of Colorectal Carcinoma. Seminars in Colon and Rectal Surgery. 2007; In Press.
View in: PubMed

Robert Levy. New core facility provides a common home for high-tech analysis of tumor images. Inside the Institute. 2007; 12(5):1.
View in: PubMed

Van Den Abbeele AD, Barnes AS, De Vries DJ, Yap JT, Reichardt P, Casalli PG, Von Mehren M, O'Neel J, Hayes W, Demetri GD. Assessment of response using FDG-PET and CT in a phase I study of AMN107 alone or in combination with imatinib (IM) in patients with imatinib-resistant (IM-R) gastrointestinal stromal tumors (GIST). J Clin Oncol. 2006 Jun 20; 24(18_suppl):3087.
View in: PubMed

Jacobsen E, Van Den Abbeele AD, Neuberg D, Li S, Fisher DC, Friedberg J, Barnes AS, Yap JT, Kutok J, Freedman AS. Inhibiting TNFa with etanercept in relapsed/refractory follicular lymphoma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):17525.
View in: PubMed

Raut CP, Van Den Abbeele A, Ramaiya N, Morgan JA, George S, Quigley MT, Dollard AM, Bertagnolli MM, Baum C, Demetri GD. Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST). J Clin Oncol. 2006 Jun 20; 24(18_suppl):9547.
View in: PubMed

Lin NU, Carey LA, Liu MC, Younger J, Come SE, Bullitt E, Van Den Abbeele AD, Li X, Hochberg FH, Winer EP. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):503.
View in: PubMed

Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006 Jun; 47(6):1059-66.
View in: PubMed

Dileo P, Bauer S, Van den Abbeele AD, Morgan JA, George S, Salesi JM, Veronese L, Manley P, Fletcher JA, Demetri GD. Results with AMN107, a novel kinase inhibitor, in gastrointestinal stromal tumor (GIST): preclinical rationale and early results in a patient (Pt) with imatinib (IM)-resistant GIST. American Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium; San Francisco, CA. 2006.
View in: PubMed

Lin NU, Carey LA, Liu MC, Come SE, Bullitt E, Van den Abbeele AD, Li X, Hochberg FH, Winer EP. Pahe II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. American Society of Clinical Oncology (ASCO). 2006; 24:3s.
View in: PubMed

Van den Abbeele AD, Barnes AS, de Vries DJ, Yap JT, Reichardt P, Casalli PG, Von Mehren M, O'Neel J, Hayes W, Demetri GD. Assessment of response using FDG-PET and CT in a phase I study of AMN107 alone or in combination with imatinib (IM) in patients with imatinib-resistant (IM-R) gastrointestinal stromal tumors (GIST). American Society of Clinical Oncology (ASCO). 2006; 24:142s.
View in: PubMed

Van den Abbeele AD, Melenevsky Y, de Vries D, Manola J, Dileo P, Tetrault R, Baum C, Badawi RD, Demetri G. FDG-PET imaging demonstrates metabolic response to SU11248 (sunitinib malate) within 7 days in GIST patients resistant to or intolerant of imatinib mesylate. ICACT. 2006; 17:241.
View in: PubMed

Raut CP, Van den Abbeele AD, Ramaiya N, Morgan JA, George S, Quigley MT, Dollard AM, Bertagnolli MM, Baum C, Demetri GD. Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST). American Society of Clinical Oncology. 2006; 24:531s.
View in: PubMed

Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, Silverman SG, Van den Abbeele AD, vanSonnenberg E, Demetri G. Clonal Evolution of Resistance to Imatinib in Patients with Metastic GIST: Molecular and Radiologic Evaluation of New Lesions. 2006.
View in: PubMed

Jacobsen E, Van den Abbeele AD, Neuberg D, Li S, Fisher DC, Friedberg J, Barnes AS, Yap JT, Kutok J, Freedman AS. Inhibiting TNF with etanercept in relapsed/refractory follicular lymphoma. American Society of Clinical Oncology (ASCO). 2006; 24:682s.
View in: PubMed

Evans TR, Morgan JA, van den Abbeele AD, McPherson IR, George S, Crawford D, Mastrullo JM, Cheng S, Fletcher JA, Demetri GD. Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):3034.
View in: PubMed

van den Abbeele A, Melenevsky Y, de Vries D, Manola J, Dileo P, Tetrault R, Baum C, Badawi R, Demetri G. Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST). J Clin Oncol. 2005 Jun; 23(16_suppl):9006.
View in: PubMed

Burrell SC, Van den Abbeele AD. 2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography of the head and neck: an atlas of normal uptake and variants. Mol Imaging Biol. 2005 May-Jun; 7(3):244-56.
View in: PubMed

Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology. 2005 Jun; 235(3):892-8.
View in: PubMed

Ng AK, Bernardo MV, Silver B, Van Den Abbeele A, Stevenson MA, Fisher DC, Mauch PM. Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2005 Jan 01; 61(1):175-84.
View in: PubMed

Dileo P, Van den Abbeele AD, Manola J, Desai J, Morgan JA, George S, St. Armand MW, Baum C, Demetri GD. Qualitative assessment of FDG PET correlates with clinical benefit in patients with imatinib mesylate-resistant GIST treated with multi-targeted tyrosine kinase inhibitor SU11248. American Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium; Hollywood, FL. 2005.
View in: PubMed

Sullivan DC, Kelloff G. Seeing into cells: the promise of in vivo molecular imaging in oncology. 2005.
View in: PubMed

Van den Abbeele AD, Melenevsky Y, de Vries DJ, Manola J, Dileo P, Tetrault R, Baum C, Badawi R, Demetri GD. Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST). American Society of Clinical Oncology (ASCO); Orlando, FL. 2005.
View in: PubMed

Van den Abbeele AD, Israel DA, Lechpammer S, Badawi RD. Positron Emission Tomography Imaging for Tumor Ablation. Tumor Ablation: Principles and Practice. 2005; 121-134..
View in: PubMed

Van den Abbeele AD, Israel DA, Lechpammer S, Badawi RD. Tumor Ablation: Principles and Practice. 2005; 121-134..
View in: PubMed

Van den Abbeele AD, Melenevsky Y, de Vries D, Manola J, Dileo P, Tetrault R, Baum C, Badawi RD, Demetri GD. FDG-PET imaging demonstrates kinase target inhibition by sunitinib malate (SU11248) in GIST patients resistant to or intolerant of imatinib mesylate. The European Cancer Conference (ECCO 13); Paris, France. 2005.
View in: PubMed

McCollum AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, Posner MR, Van den Abbeele AD. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004 Oct; 26(10):890-6.
View in: PubMed

Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res. 2004 Sep 01; 10(17):5732-40.
View in: PubMed

Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Tuncali K, Silverman SG, Van Den Abbeele AD, Vansonnenberg E, Demetri GD. Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3010.
View in: PubMed

Van Oosterom AT, Dumez H, Desai J, Stroobants S, Van Den Abbeele AD, Clement P, Shand N, Kovarik J, Tsyrlova A, Demetri GD. Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3002.
View in: PubMed

Demetri GD, Desai J, Fletcher JA, Morgan JA, Fletcher CD, Kazanovicz A, Van Den Abbeele A, Baum C, Maki R, Heinrich MC. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3001.
View in: PubMed

Holdsworth CH, Manola J, Badawi RD, Israel DA, Blanke C, Von Mehren M, Joensuu HT, Dimitrijevic S, Demetri GD, Van Den Abbeele AD. Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3011.
View in: PubMed

Dileo P, Randhawa R, Vansonnenberg E, Shankar S, Desai J, Morgan JA, Tuncali K, Van Den Abbeele A, Silverman SG, Demetri GD. Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM). J Clin Oncol. 2004 Jul 15; 22(14_suppl):9024.
View in: PubMed

Van Den Abbeele AD, Badawi RD, Manola J, Morgan JA, Desai J, Kazanovicz A, Armand MS, Baum C, Demetri GD. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3012.
View in: PubMed

Van Oosteram AT, Dumez H, Desai J, Stroobants S, Van den Abbeele A, Clement P, Shand N, Kovarik J, Tsyrlova A, Demetri GD. Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001)and imatinib mesylate (IM, Glivac/Gleevac) in patients with gastrointestinal stromal tumor (GIST)refractory to IM. American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA. 2004.
View in: PubMed

Van den Abbeele AD, Badawi RD, Manola J, Morgan J, Desai J, Kazanovicz A, St. Amand M, Baum C, Demetri GD. Effects of cessation of imatinib mesylate therapy in patients with IM-refractory gastrointestinal stromal tumors (GIST)as visualized by FDG-PET scanning. American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA. 2004.
View in: PubMed

Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Tuncali K, Silverman SG, Van den Abbeele AD, vanSonnenberg E, Demetri GD. Clonal evaluation of resistance to imatinib in patients with gastrointestinal stromal tumor (GIST): Molecular and radiologic evaluation of new lesions. American Society of Clinical Oncology (ASCO)Conference. New Orleans, LA. 2004.
View in: PubMed

Dileo P, Randhawa R, Vansonnenberg E, Shankar S, Desai J, Morgan JA, Tuncali K, Van den Abbeele A, Silverman SG, Demetri GD. . Safety and efficacy of percutaneous Radio-Frequency Ablation (RFA)in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)with clonal evolution of lesions refractory to imatinib mesylate (IM). American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA. 2004.
View in: PubMed

Van den Abbeele AD, Badawi RD, Manola J, Morgan J, Desai J, Kazanovicz A, St Amand M, Baum C, Demetri GD. . Effects of cesssation of imatinib mesylate (IM) therapy in patients (pts) with IM-refactory gastrointestinal stromal tumors (GIST)as visualized by FDG-PET scanning. American Soceity of Clinical Oncology (ASCO) Conference. 2004.
View in: PubMed

Van Oosteram AT, Dumez H, Desai J, Stroobants S, Van den Abbeele A, Clement P, Shand N, Kovarik J, Tsyrlova A, Demetri GD. . Combination signal transduction inhibition: a phase 1 and 2 trial of the oral mTOR-inhibitor everolimus (ERAD001) and imatinib mesylate (IM, Glivac r/Gleevac r) in patients (pts) with gastrointestinal stromal tumor (GIST) refactory to IM. American Society of Clinical Oncology (ASCO) Conference. 2004.
View in: PubMed

Demetri GD, Desai J, Fletcher JA, Morgan JA, Fletcher CD, Kazanovicz A, Van den Abbeele A, Baum C, Maki R, Heinrich MC. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome Imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). New Orleans, LA. American Society of Clincal Oncology (ASCO) Conference. 2004.
View in: PubMed

Demetri GD, Benjamin R, Blanke CD, Haesun C, Corless C, DeMatteo RP, Eisenberg BL, Fletcher CDM, Maki RG, Rubin B, Van den Abbeele AD, vonMehren M. Optimal management of patients with gastrointestinal stromal tumors (GIST). 2004.
View in: PubMed

Dileo P, Randhawa R, Vansonnenberg E, Shankar S, Desai J, Morgan JA, Tuncali K, Van den Abbeele A, Silverman SG, Demetri GD. Safety and efficacy of percutaneous Radio-Frequency Ablation (RFA)in patients (Pts) with metastatic gastrointestinal stromal tumor (GIST)with clonal evolution of lesions refractory to imatinib mesylate (IM). American Society of Clinical Oncology (ASCO) Conference. 2004.
View in: PubMed

Demetri GD, Benjamin R, Blanke CD, Choi H, Corless C, DeMatteo RP, Eisenberg BL, Fletcher CD, Maki RG, Rubin BP, Van den Abbeele AD, von Mehren M. NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2004 May; 2 Suppl 1:S-1-26; quiz 27-30.
View in: PubMed

Desai J, Shankar S, Heinrich MC, Fletcher CD, Tuncali K, Silverman SG, Van den Abbeele AD, vanSonnenberg E, Demetri GD. Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST). Molecular and radiologic evalution of new lesions. American Society of clinical Oncology (ASCO) Conference. 2004.
View in: PubMed

Van den Abbeele AD. . The era of molecular therapy: redifining the treatment of gastrointestinal stromal tumors (GIST). 2004.
View in: PubMed

Demetri GD, Desai J, Fletcher JA, Morgan JA, Fletcher CD, Kazanovicz A, Van den Abbeele A, Bacum C, Maki R, Heinrich MC. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome Imatinib (IM) resistance caused by stromal tumor (GIST). American Society of Clinical Oncology (ASCO)Conference. 2004.
View in: PubMed

Blanke C, Joensuu H, Demetri G, Heinrich M, Roberts P, Eisenberg B, Fletcher J, Fletcher C, Corless C, Dimitrijevic S, Van den Abbeele A, Kiese B, McDougall K, von Mehren M. Long-term follow up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. Gastrointestinal Cancers Symposium; San Francisco, CA. 2004.
View in: PubMed

Blanke C, Joensuu H, Demetri G, Heninrich M, Roberts P, Eisenberg B Fletcher J, Fletcher C, Corless C, Dimitrijevic S, Van den Abbeele A, Kiese B, McDougall K, von Mehren M. Long-term follow upof advanced gastrointestinal stromal tumors (GIST) patients treated with imatinib mesylate. Gastointestinal Cancers Symposium . 2004.
View in: PubMed

Desai J, Maki R, Heinrich MC, Fletcher JA, Ryan D, Morgan JA, St. Amand M, George S, Manola J, Baum C, Cohen DP, Corless CL, Fletcher CD, Van den Abbeele AD, Demetri GD. Activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU011248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. American Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium; San Francisco, CA. 2004.
View in: PubMed

Holdsworth CH, Manola J, Badawi RD, Israel DA, Blanke, C, von Mehren M, Joensuu H, Dimitrijevic S, Silberman S, Demetri GD and Van den Abbeele AD. Use of Computerized Tomography as an Early Prognostic Indicator of Response to Imatinib Mesylate in Patient with Gastrointestinal Stromal Tumors (GIST). Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA. 2004.
View in: PubMed

Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, Mauch PM, Canellos GP, van den Abbeele AD. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma. 2004 Jan; 45(1):85-92.
View in: PubMed

Van den Abbeele AD, Lechpammer S, Tetrault RJ, Badawi RD. Non-Hodgkin's Lymphomas. 2004; 155-169.
View in: PubMed

Desai J, Shankar S, Heinrich MC, Fletcher JA, George S, Van den Abbeele AD, vanSonnenberg E, Demetri GD. A CME newsletter publication covering key clinical issues in the management of GIST, including highlights from the 2003 CTOS annual meeting and Helsinki GIST symposium. 2004.
View in: PubMed

Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003 Dec 01; 21(23):4342-9.
View in: PubMed

EI Fakhri G, Holdsworth CH, Santos PA, Badawi RD, Van den Abbeele AD and Kijewski MF. . Impact of patient size, aquisition mode, reconstruction algorithm, and randoms and attenuation corrections on lesion detection and activity estmiation in whole-body FDG-PET. IEEE Medical Imaging Conference. 2003.
View in: PubMed

Bindra J, Israel DA, Van den Abbeele AD. Physiologic and benign causes of FDG uptake in oncologic FDG-PET imaging. Radiological Society of North America (RSNA)Conference. 2003.
View in: PubMed

El Fakhri G, Holdsworth CH, Santos PA, Badawi RD, Van den Abbeele AD and Kijewski MF. . Impact of patients size, Acquisition mode, reconstruction algorithm, and random and attenuation corrections on lesion detection and activity estimation in whole-body FDG-PET. IEEE Medical Imaging Conference. 2003.
View in: PubMed

Bindra J, Israel DA, Van den Abbeele AD. . Physiologic and benign causes of FDG uptake in oncologic FDG-PET imaging. Radiological Society of North America (RSNA) Conference. Chicago, IL. 2003.
View in: PubMed

Holdsworth CH, Badawi RD, Santos PA, Van den Abbeele AD and El Fakhri G. Evaluation of a Model Based Scatter Correction in Clinical 3D PET. IEEE Medical Imaging Conference. Portland, OR. 2003.
View in: PubMed

Holdsworth CH, Badawi RD, Santos PA, Van den Abbeele AD and EI Fakhri G. Evaluation of a Monte Carlo scatter correction in clinical 3D PET. IEEE Medical Imaging Conference. 2003.
View in: PubMed

El Fakhri G, Holdsworth CH, Santos PA, Badawi RD, Van den Abbeele AD and Kijewski MF. Impact of patient size, acquisition mode, reconstruction algorithm, and randoms and attenuation corrections on lesion detection and activity estimation in whole-body FDG-PET. IEEE Medical Imaging Conference. Portland, OR. 2003.
View in: PubMed

Radjadhyaksha CD, D Neuberg S Li, Fischman AJ, Van den Abbeele AD. Prospective comparison of imaging findings in the lung, hilum and spleen on FDG-PET and GA-67 scintigraphy in patients with hodgkin's disease prior to and following chemotherapy with ABVD. Radiological Society of North America (RSNA) Conference. Chicago, IL. 2003.
View in: PubMed

Radjahyaksha CD, D Neuberg S Li, Fischman AJ, Van den Abbeele AD. Prospective comparison of imaging finding in the lung, hilum and spleen on FDG-PET and GA-67 scintigraphy in patients with hodgkin's disease prior to and following chemotherapy with ABVD. Radiological Society of North America (RSNA) Conference. . 2003.
View in: PubMed

Cherrington JM, Van den Abbeele A, Badawi RD, Lechpammer S, McCarthy TJ, Corless CL, ChoenDP, Scigalla P, Fletcher JA, and Demetri GD. Assessing biological responses to SU11248 in a Phase I clinical trial of patients with imatinib -resistant gastrointestinal stromal tumors (GIST):. Pharmacodynamic evaluation using 18 FDG-PET functional imaging, pharmacokinetics, and modulation of blood biomarkers. 2003.
View in: PubMed

Cherrington JM, Van den Abbeele A, Badawi RD, Lechpammer S, McCarthy TJ, Manning WC, DePrimo SE, O'Farrell AM, Bello CL, Cohen DP, Scigalla P, Fletcher JA and Demetri GD. Assessing biological responses to SU11248 in a Phase I clinical trial of patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Pharmacodynamic evaluation using FDG-PET functional imaging, pharmacokinetics, and modulation of blood biomarkers. ISMRM Workshop on Cellular and Molecular Imaging in Diagnostics and Therapy. Orlando, FL. 2003.
View in: PubMed

Van den Abbeele AD, Lechpammer S, Tetrault RJ, Badawi RD. Non-Hodgkin's Lymphomas. Nuclear Medicine. 2003.
View in: PubMed

Demetri GD, Heinrich MC, George S, Manola J, Morgan JA, Desai J, St. Amand J, Cohen DP, Scigalla P, Manning WC, Cherrington JM, McCarthy TJ, Corless CL, Fletcher JA, Fletcher CDM, Van den Abbeele AD. Biological activity of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with malignant gastrointestinal Stromal tumor (GIST)refractory to imatinib mesylate. AACR. 2003; 44:967.
View in: PubMed

Shankar S, Desai J, Potter A, George S, Sherwood GK, Israel D, Dipiro P, Van den Abbeele AD, vanSonnenberg E, Demetri G. Novel patterns of progression following initial response to Imatinib in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2003; 22:230A.
View in: PubMed

Demetri GD, Heinrich MC, Fletcher JA, Fletcher CDM, George S, Desai J, Cohen DP, Scigalla P, Cherrington JM, Van den Abbeele AD. Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with malignant gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol. 2003; 22:814A.
View in: PubMed

Skarin AT, Van den Abbeele AD. A New Role for PET Scanning. The American Journal of Oncology Reivew. 2003; 367-368.
View in: PubMed

El Fakhri G, Holdsworth C, Badawi RD, Santos PA, Kijewski MF, Van den Abbeele AD, Moore SC. Dependence of performace of whole-body-FDG-PET lesion detection and activity estimation on patient size, randoms, variance reduction, and acquisition geometry. J Nucl Med. 2003; 44(5):61.
View in: PubMed

Shaffer K, Van den Abbeele AD. Radiographic Evaluation of Cancer. Atlas of Diagnostic Oncology. 2003; 5-26.
View in: PubMed

DePrimo SE, Wong LM, Nicholas SL, Manning WC, O'Farrell AM, Amand M, McConarty B, Topciu R, Kazanovic A, Van den Abbeele AD, Demetri GD, Cherrington JM. Decreases in circulating levels of soluble KIT in patients with imatinib-resistant gastrointestinal Stromal tumor (GIST) receiving the novel kinases inhibitor SU11248: Correlative analysis of blood and plasma biomarkers. AACR. 2003; 44:587.
View in: PubMed

Manning WC, Bello CL, DePrimo SE, Fletcher JA, Fletcher CDM, Van den Abbeele AD, Cohen DP, Scigalla P, Cherrington JM, Demetri GD. Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients with imatinib-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol. 2003; 22:192A.
View in: PubMed

Blasberg RG, Tjuvajev JG. Molecular-genetic imaging: current and future perspective. 2003.
View in: PubMed

Van den Abbeele AD, Badawi RD, Cliche JP, Spangler T, Janicek MJ, Israel DA, Heinrich MC, Silberman SS, Dimitrijevic S, Demetri GD. FDG-PET as a Surrogate Marker for the Response to Gleevec (Imatinib Mesylate) in Patients with Advanced Gastrointestinal Stromal Tumors (GIST). J Nucl Med. 2003; 44(5):24-25.
View in: PubMed

Van den Abbeele AD, Israel DA, Lechpammer S, Badawi RD. Pet Imaging: Tumor Ablation: Principles and Practice. 2003.
View in: PubMed

Enzinger PC, Mayer RJ. Medical Progress, Esophageal Cancer. New Engl. J. Med. 2003.
View in: PubMed

Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002 Sep; 38 Suppl 5:S60-5.
View in: PubMed

Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15; 347(7):472-80.
View in: PubMed

Badawi RD, El Fakhri G, Lechpammer S, Spangler TA, Tetrault RJ, Moore SC, Van den Abbeele AD. A comparison of 2D and 3D FDG-PET images on a high performance BGO scanner using an interleaved septa-in/septa-out acquisition protocol. Molecular Imaging and Biology. 2002; 4:44S.
View in: PubMed

McCollum AD, Van den Abbeele AD, Haddad Rl, Burrell SC, Norris CM, Tishler RB, Case MA, Posner MR. The use of FDG-PET to detect residual disease after induction chemotherapy and definite chemoradiotherapy for squamous cell cancer of the head and neck. Sixth Research Workshop on the Biology,Prevention, and Treatment of Head and Neck Cancer. 2002.
View in: PubMed

EI Fakhri G, Badawi RD, Santos PA, Moore SC, Van den Abbeele AD, Kijewski MF. Impact of acquisition geometry and size on tumor detectability in patient whole body PET:. A Channelized hotelling observer study. 2002.
View in: PubMed

George D, Febbo P, Hagman E, OH W, Gilligan T, Lofa M, Weinstein M, Badawi RD, Van den Abbeele AD, Tempany C, Moricz M, Silberman S, Richie J, Kantoff P and Bubley G. A Pilot study of Imatinib Mesylate (Gleevec) prior to prostatectomy in men with newly diagnosed prostate cancer. CaPCURE Scientific Retreat. 2002.
View in: PubMed

Van den Abbeele AD, Burrell SC, McCollum D, Spangler TA, Haddad RI, Norris CM, Tishler RB, Posner MR. The role of FDG-PET in patients with squamous cell cancer of the head and neck after sequential induction chemotherapy and definitive chemoradiotherapy. J Nucl Med. 2002; 43:P73.
View in: PubMed

Lechpammer S, Tetrault RJ, Badawi RD, Van den Abbeele. PET imaging and treatment evaluation in cancer patients. 2002.
View in: PubMed

Van den Abbeele AD. FDG-PET as a key tool in the diagnosis and monitoring of GIST. In first Successful Treatment for GIST. 2002.
View in: PubMed

Van den Abbeele AD, Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Mauch P and Canellos GP. FDG-PET is superior to gallium-67 scintigraphy in the staging and follow-up of patients with Hodgkin's disease: a prospective, blinded comparison. J Nucl Med. 2002; 43:P30-P31.
View in: PubMed

El Fakhri G, Badawi RD, Santos PA, Moore SC, Van den Abbeele AD, Kijewski MF. Impact of acquisition geometry and lesion size on tumor detectability in patient whole body PET: A channelized hotelling observer study. IEEE meeting. 2002.
View in: PubMed

Van den Abbeele AD, Badawi RD, Cliche JP, Israel D, Dimitrijevic S, Demetri G. Response to imatinib mesylate (Gleevec) therapy in patients with advanced gastrointestinal stromal tumors (GIST) is demonstrated by F-18-FDG-PET prior to anatomic imaging with CT. Radiology. 2002; 225:P424.
View in: PubMed

PET. Medstar. 2002.
View in: PubMed

Van den Abbeele AD, Badawi RD, Cliche JP, Janicek M, Tetrault R, Spangler T, Potter A, Merriam P, Silberman S, Dimitrijevic S, Demetri GD. F-FDG-PET predicts response to Imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2002; 21:P403a.
View in: PubMed

George D, Febbo P, Hagman E, OH W, Gilligan T, Lofa M, Weinstein M, Badawi RD, Van den Abbeele AD, Tempany C, Moricz M, Silberman S, Riche J, Kantoff P and Bubley G. A Pilot study Imatinib Mesylate prior to prostatectomy in men with newly diagnosed prostate cancer. 2002.
View in: PubMed

A day in the life of the Dana-Farber Cancer Institute. 2001.
View in: PubMed

McCollum D, Van den Abbeele AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case Ma, Lake-Willcutt B, Posner MR. The use of FDG-PET to detect residual disease after sequential therapy with induction chemotherapy and definitive chemoradiotherapy for squamous cell cancer of the head and neck. The second International Chicago Symposium on Malignancies of the Chest and Head and neck. 2001.
View in: PubMed

McCollum D, Van den Abbeele AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, Lake-Willcutt B, Posner MR. The use of FDG-PET to detect residual disease after sequential therapy with induction chemotherapy and definitive chemoradiotherapy for squamous cell cancer of the head and neck. The Second International Chicago Symposium on Malginancies of the Chest and Head & Neck. 2001; abst. 76.
View in: PubMed

Friedberg JW, Canellos GP, Neuberg D, Kim H, Mauch P, Van den Abbeele. A prospective blinded comparison of positron emission tomography(PET)with gallium/SPECT scintigraphy in the staging and follow-up of patients with de novo Hodgkin's disease. International Lymphoma Conference, Lausanne. 2001.
View in: PubMed

Friedberg JW, Canellos GP, Neuberg D, Kim H, Mauch P, Van den Abbeele. A prospective blind comparison of positron emission tomography (PET) with gallium/SPECT scintigraphy in the staging and follow up of patients with de novo Hodgkin's disease. 2001.
View in: PubMed

The role of PET in patients with cancer. 2001.
View in: PubMed

GIST tumors and Glivec. 2001.
View in: PubMed

The role of PET in patients with GIST. 2001.
View in: PubMed

Losken A, Swartz MA, Van Den Abbeele AD, Jain RK, Slavin SA. A potential murine model for flap-related investigations. Plast Reconstr Surg. 2001 May; 107(6):1504-8.
View in: PubMed

Van den Abbeele AD, for the GIST Collaborative PET Study Group. F18-FDG-PET provides early evidence of biological response to ST1571 in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2001; 20:P362a.
View in: PubMed

Breast Cancer. 2001.
View in: PubMed

The Power of Positron Emission Tomography (PET). 2001.
View in: PubMed

Jacobson AF, Shapiro CL, Van den Abbeele AD, Kaplan WD. Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer. 2001 Jan 01; 91(1):17-24.
View in: PubMed

PET documents Gleevec tumor-fighting power. Diagnostic Imaging. 2001; 1(2):4.
View in: PubMed

Frank DA, Meuse J, Hirsch D, Ibrahim JG, van den Abbeele AD. The treatment and outcome of cancer patients with thromboses on central venous catheters. J Thromb Thrombolysis. 2000 Dec; 10(3):271-5.
View in: PubMed

Uncovering Cancer. The use of radioactive tracers. 2000.
View in: PubMed

PET scanners. 2000.
View in: PubMed

Frohlich DE, Chen JL, Neuberg D, Kehoe KM, Van den Abbeele AD. When is hilar uptake of 67Ga-citrate indicative of residual disease after CHOP chemotherapy? J Nucl Med. 2000 Feb; 41(2):269-74.
View in: PubMed

Moore SC, El Fakhri G, Badawi R, Van den Abbeele AD, Zimmerman RE. Relative lesion detectability in 3D vs. 2D dedicated multi-ring PET. IEEE meeting 2000, Lyon, France. 2000.
View in: PubMed

PET scanner is enhancing cancer diagnosis. 2000.
View in: PubMed

Jones A. Positron Emission Tomography (PET). 2000.
View in: PubMed

Fey CP, Van den Abbeele AD. Scintigraphy of neoplastic disease. Teaching Atlas of Nuclear Medicine. Donohoe K, Van den Abbeele. 2000; 224-234.
View in: PubMed

Van den Abbeele AD. Lymphoscintigraphy. Teaching Atlas of Nuclear Medicine. Donohoe K, Van den Abbeele A. 2000; 369-374.
View in: PubMed

Van den Abbeele AD, Fey CP. Vascular Scintigraphy. Teaching Atlas of Nuclear Medicine. 2000; 429-439.
View in: PubMed

Janicek MJ, Fey CP, Van den Abbeele AD. Scintigraphy of neoplastic disease. Teaching Atlas of Nuclear Medicine. Donohoe K, Van den Abbeele. 2000; 235-246.
View in: PubMed

Advances at the Frontier of Cancer Diagnosis: PET scanner opens a window on cancer. Paths of Progress. 2000.
View in: PubMed

Moore SC, EI Fakhri G, Badawi R, Van den Abbeele AD, Zimmerman RE. . Relative Lesion detectability in 3D vs. 2D dedicated multi-ring PET. 2000.
View in: PubMed

Van den Abbeele AD. Scintigraphy of neoplastic disease. Teaching Atlas of Nuclear Medicine. 2000; 199-216.
View in: PubMed

McCollum AD, Van den Abbeele AD, Haddad RI, Burrell SC, Norris CM, Tishler RB, Case MA, Posner MR. The use of FDG-PET to detect residual disease after induction chemotherapy and definite chemoradiotherapy for squamous cell cancer of the head and neck. Sixth Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer. Virginia. 2000.
View in: PubMed

Donohoe D, Van den Abbeele A. Teaching Atlas of Nuclear Medicine. 2000.
View in: PubMed

VanSonnenberg E, Silverman SG, Shankar S, Tuncali K, Van den Abbeele AD, Meyerovitz M, Whang E. Large and multiple hepatic lesions: Strategies and rationale for radiologic tumor ablation. RSNA Annual Meeting. 2000.
View in: PubMed

VanSonnenberg E, Silverman SG, Shankar S, Tuncali K, Van den Abbeele AD, Meyerovitz M, Whang E. . Large and multiple hepatic Lesions. Strategies and rationale for radiologic tumor ablation. 2000.
View in: PubMed

Friedberg JW, Van den Abbeele AD, Kehoe K, Singer S, Fletcher CD, Demetri GD. Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. Cancer. 1999 Oct 15; 86(8):1621-7.
View in: PubMed

Slavin SA, Van den Abbeele AD, Losken A, Swartz MA, Jain RK. Return of lymphatic function after flap transfer for acute lymphedema. Ann Surg. 1999 Mar; 229(3):421-7.
View in: PubMed

Wu C, Vasconcelles M, DePiro P, Van den Abbeele A, Rakusin A, Bechard K, Skarin A. Primary cardiac angiosarcoma presenting as a malignant pericardial effusion. J Clin Oncol. 1998 Dec; 16(12):3913-5.
View in: PubMed

Kassis AI, Wen PY, Van den Abbeele AD, Baranowska-Kortylewicz J, Makrigiorgos GM, Metz KR, Matalka KZ, Cook CU, Sahu SK, Black PM, Adelstein SJ. 5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med. 1998 Jul; 39(7):1148-54.
View in: PubMed

Borras-Boneu G, Van den Abbeele AD, Kassis AI. Biodistribution of radiolabeled MOv18 in nude mice bearing ovarian cancer xenografts. Proceeding of the Fourth International Conference on Monoclonal Antibody lmmunoconjugates for Cancer. 1998; 97.
View in: PubMed

Wagenaar DJ, Zimmerman RE, Hill TC, Kolodny GM, Van den Abbeele AD. Comparison of Dual-Head Gamma Camera System Sensitivity at 511 keV using a Distance-Dependent Method. American Association of Physicists in Medicine 39th Annual Meeting and Exhibition. Milwaukee, WI. 1997.
View in: PubMed

Wagenaar DJ, Zimmerman RE, Hill TC, Kolodny GM, Van den Abbeele AD. . Comparison of Dual-Head Gamma Camera System Sensitivity at 511 KeV using a Distance-Dependent Method. American Association of Physicists in Medicine a 39th Annual Meeting and Exhibition. 1997.
View in: PubMed

Bartold SP, Donohoe KJ, Fletcher JW, Haynie TP, Henkin RE, Silberstein EB, Royal HD, Van den Abbeele A. Procedure guideline for gallium scintigraphy in the evaluation of malignant disease. Society of Nuclear Medicine. J Nucl Med. 1997 Jun; 38(6):990-4.
View in: PubMed

Slavin SA, Upton J, Kaplan WD, Van den Abbeele AD. An investigation of lymphatic function following free-tissue transfer. Plast Reconstr Surg. 1997 Mar; 99(3):730-41; discussion 742-3.
View in: PubMed

Van den Abbeele AD, Rybicki FJ, Cowart DM, Kehoe KM. Quantification of gallium-67 avidity as a function of the histology in patients with non-Hodgkin's lymphoma. J Nucl Med. 1997; 38:P238.
View in: PubMed

Van den Abbeele AD, Shulkin BL, Neuberg DS, Kehoe KM. The role of SPECT in the evaluation of the abdomen on gallium-67 scintigraphy. J Nucl Med. 1997; 38:P115.
View in: PubMed

Wagenaar DJ, Golden E, Van den Abbeele AD, kolodny GM. Determinination of the visibility of simulated lesions in background with 511 KeV SPECT. Proceedings of the European Conference on Research and Application of Positron Emission Tomography in Oncology PET and Cancer. 1996.
View in: PubMed

Wagenaar DJ, Golden E, Van den Abbeele AD, Kolodny GM. Determination of the visibility of simulated lesions in background with 511 keV SPECT. European Conference on Research and Application of Positron Emission Tomography in Oncology PET and Cancer, Groningen University Hospital, The Netherlands. 1996.
View in: PubMed

Kassis AI, Tumeh SS, Wen PY, Baranowska-Kortylewicz J, Van den Abbeele AD, Zimmerman RE, Carvalho PA, Garada BM, DeSisto WC, Bailey NO, Castronovo FP, Mariani G, Black PM, Adelstein SJ. Intratumoral administration of 5-[123I]iodo-2'-deoxyuridine in a patient with a brain tumor. J Nucl Med. 1996 Apr; 37(4 Suppl):19S-22S.
View in: PubMed

Van den Abbeele AD, Tutrone RF, Berman RM, Baranowska-Kortylewicz J, Barclay PD, Richie JP, Adelstein SJ, Kassis AI. Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer. J Nucl Med. 1996 Feb; 37(2):315-20.
View in: PubMed

Kassis AI, Tumeh SS, Wen PYC, Baranowska-Korylewicz J, Van den Abbeele AD, Zimmerman RE, Carvalho PA, Garade BM, DeSisto WC, Baily NO, Castronovo FP,Mariani G, Black PMcL, Adelstein SJ. . Intratumoral administration of 5-[123/]iodo-2-deoxyurdine in a patients with a brain tumor. Adelstein SJ, Kassis AI, eds. Processing of symposium on clinical application of radiolabeled IUdR. 1996; 37:(Suppl) 19S-22S.
View in: PubMed

Van den Abbeele AD. Octreotide scintigraphy. 1996.
View in: PubMed

Van den Abbeele AD. Tumor and Inflammatory conditions. 1996.
View in: PubMed

Nagel JS, Van den Abbeele AD. Scrontium-89 radiotherapy for painful bony metastases. 1996.
View in: PubMed

Wagenaar DJ, Van den Abbeele AD, Kolodny GM, Hill TC, Zimmerman RE. A world wide web-based resource for the physical evaluation of 511 keV-collimated imaging. J Nucl Med. 1996; 37:P305.
View in: PubMed

Wagenaar DJ, Golden E, Van den Abbeele AD, Kolodny GM. Determination of the visibility of simulated lesions in background with 511 KeV SPECT. In Paans AMJ, Pruim J, Franssen EJF, Vaalburg W, eds.+. Metabolic imaging of cancer. Proceedings of the Europeans Conference on Research and Application of Positron Emission Tomography in Oncology. 1996.
View in: PubMed

Nagel JS, Van den Abbeele AD. Scrontium-89 radiotherapy for painful bony metastases. 1996.
View in: PubMed

A Patient Guide to Nuclear Medicine at the Dana-Farber Cancer Institute. Divsion of Nuclear Medicine at the DFCI. 1996.
View in: PubMed

Arthur JE, Kehoe K, Van den Abbeele AD. . Thallium-201 scintigraphy in low grade non-Hodgkin's lymphoma. J Nucl Med. 1996; 37:P258.
View in: PubMed

Van den Abbeele AD, Slavin SA. Classification of upper extremity lymphedema via lymphoscintigraphy. J Nucl Med. 1996; 37:P261.
View in: PubMed

Van den Abbeele AD, Scheiner JD. Lymphoscintigraphy. 1996.
View in: PubMed

Gangopadhyay A, Saravis CA, van den Abbeele AD, Kassis AI. pI-dependent isolation of antibody isoforms by semipreparative isoelectric focusing. Q J Nucl Med. 1995 Jun; 39(2):129-33.
View in: PubMed

Buonomo C, Van den Abbeele AD. Inflammation and infection. Pediatric Nuclear Medicine. 1995; 540-549.
View in: PubMed

Van den Abbeele AD, Craveiro EM, Manganella JH, Kaplan WD. Lymphatic imaging and its multiple roles in clinical practice. J Nucl Med. 1995; 36:P222.
View in: PubMed

Van den Abbeele AD. . Scintigraphy of lymphoma. 1995.
View in: PubMed

Van den Abbeele AD. Monoclonal antibodies: A review of the basics. 1994.
View in: PubMed

Gangopadhyay A, Van den Abbeele AD, Kassis AI. Modification of Mouse IgG isoelectric point following radioiodination. Antibody Immunoconj Radiophar. 1994; 7:171-178..
View in: PubMed

Mariani G, Collecchi P, Giuliani L, Baranowska-Kortylewicz J, Di Luca L, Meucci G, Viacava P, Van den Abbeele AD, Salvadori PA, Di Sacco S, et al. Tumor targeting potential and metabolism of 5-[125I]iodo-2'-deoxyuridine injected intratumorally in patients with breast cancer. Ann N Y Acad Sci. 1993 Nov 30; 698:204-11.
View in: PubMed

Smith SV, Van den Abbeele AD, Baranowska-Kortylewicz J, Jones PL, Lambrecht RM, Adelstein SJ, Kassis Al. A new three-step strategy using the avidin-biotin system for radioimaging tumors. Abstracts of the Tenth International Symposium on Radiopharmaceutical Chemistry, Kyoto, Japan. 1993; 392(3).
View in: PubMed

Smith SV, Van den Abbeele AD, Baranowska-Kortylewicz J, Jones PL, Lambrecht RM, Adelstein SJ, Kassis AI. . A new three-step strategy using the avidin-biotin system for radioimaging tumors. Abstracts of the Tenth International Symposium in Radiopharmaceutical Chemistry,. 1993; 392-3.
View in: PubMed

Mariani G, Cei A, Collecchi P, Baranowska-Kortylewicz J, Van den Abbeele AD, Di Luca L, Di Stefano R, Viacava P, Ferdeghini EM, Di Sacco S, et al. Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2'-deoxyuridine following intratumoral injection in patients with colorectal cancer. J Nucl Med. 1993 Jul; 34(7):1175-83.
View in: PubMed

Smith SV, Van den Abbeele AD, Baranowska-Kortylewicz, Jones PL, Lambrecht RM, Adelstein SJ, Black PMcL, Kassis AI. A three-step procedure for the targeting of tumors using the avidin-biotin system. Presented at the Australia/ New Zealand Society of Nuclear Medicine scientific Meeting. 1993.
View in: PubMed

Smith SV, Van den Abbeele AD, Baranowska-Kortylewicz J, Jones PL, Lambrecht RM, Adelstein SJ, Black PMcL, Kassis Al. A three-step procedure for the targeting of tumors using the avidin-biotin system. Australia/New Zealand Society of Nuclear Medicine Scientific Meeting, Canberra, Australia. 1993.
View in: PubMed

Van Den Abbeele AD. Monoclonal antibodies: From basics to clinical implementation. 1993.
View in: PubMed

Mariani G, Collecchi P, Giuliani L, Baranowska-Kortylewicz J, Di Luca L, Meucci G, Viacava P, Van den Abbeele AD, Salvadori PA, Di Sacco S, Adelstein SJ, Bevilacqua G, Kassis AI. . Tumor targeting potential and metabolism of 5-[125]iodo 2-deoxyuridine injected intratumorally in patients with breast Cancer. Ann NY Acad sc. 1993; 698:204-11.
View in: PubMed

Mariani G, Giuliani L, Baranowska-Kortylewicz J, Collecchi P, Meucci G, Di Luca L, Viacava P, Van den Abbeele AD, Bevilacqua G, Salvadori PA, Adelstein SJ, Kassis AI. Intratumoral injection of 5[123]iodo-2-dexyuridine in patients with breast cancer. In Hofer R, Bergmann H, Sinzinger H, eds. Radioactive isotopes in clinical medicine and research. 1993; 188-93.
View in: PubMed

Khawli LA, van den Abbeele AD, Kassis AI. N-(m-[125I]iodophenyl)maleimide: an agent for high yield radiolabeling of antibodies. Int J Rad Appl Instrum B. 1992 Apr; 19(3):289-95.
View in: PubMed

Van den Abbeele AD, Baranowska-Kortylewicz J, Adelstein SJ, Carvalho PA, Tutrone RF, Riche JP, Wen PYC, Black PMcL, Mariani G Kassis AI. Diagnostic and therapeutic application of Auger-electrons-emitting 5[123/125]iodo-2-deoxyuridine in cancer. In Howell RW, Narra VR, Sastry KSR, Rao DV, eds Biophysical aspect of Auger processes, AAPM Symposium Proceeding number 8. 1992; 372-395.
View in: PubMed

Mariani G, Cei A, Giuliani L, Baranowska-Kortylewicz J, Collecchi P, Meucci G, Di Lucca L, Viacava P, Van den Abbeele AD, Bevilacqua G, Salvadori PA, Adelstein SJ, Kassis AI. Tumor targeting potential and metabolism of 5-[125]iodo-2-deoxyurdine injected intratumorally in patients with gastrointestinal or breast cancers. J Nucl Biol Med. 1992; 154-7.
View in: PubMed

Baranowska-Kortylewicz J, Makrigiorgos GM, Van den Abbeele AD, Berman RM, Adelstein SJ, Kassis AI. 5-[123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys. 1991 Nov; 21(6):1541-51.
View in: PubMed

Van den Abbeele AD, Baranowska- Kortylewicz J, Mariani G, Adelstein SJ, Kassis AI. Diagnostic and therapeutic applications of the Auger electrons-emitting 5-[123/125/]iodo-2-deoxyuridine in cancer. Presented at the Second International Symposium on Biophysical Aspect of Auger Processes, Amherst. 1991.
View in: PubMed

Van den Abbeele AD, Baranowska-Kortylewicz J, Mariani G, Adelstein SJ, Kassis Al. Diagnostic and therapeutic applications of the Auger electron-emitting 5-[123/125/]iodo-2'-deoxyuridine in cancer. Second International Symposium on Biophysical Aspects of Auger Processes, Amherst, MA. 1991.
View in: PubMed

Janicek MJ, Van den Abbeele AD, DeSisto WC, Kassis AI, Holman BL, Tumeh SS, Hollenberg NK. Embolization of platelets after endothelial injury to the aorta in rabbits. Assessment with 111indium-labeled platelets and angiography. Invest Radiol. 1991 Jul; 26(7):655-9.
View in: PubMed

Mariani G, Ito S, Nayak RC, Baranowska-Kortylewicz J, Venkateshan CN, Van den Abbeele AD, Eisenbarth GS, Adelstein SJ, Kassis AI. Capping and internalization of a monoclonal antibody-surface antigen complex: a possible mode of interaction of monoclonal antibodies and tumor cells. J Nucl Biol Med. 1991 Apr-Jun; 35(2):111-9.
View in: PubMed

Van den Abbeele AD, Aaronson RA, Daher S, Taube RA, Adelstein SJ, Kassis AI. Antigen-binding site protection during radiolabeling leads to a higher immunoreactive fraction. J Nucl Med. 1991 Jan; 32(1):116-22.
View in: PubMed

Tumeh SS, Carvalho PA, van den Abbeele AD, Maguire JH, Rauh DA, Neptune M, Kassis AI. Detection of focal infection by 111In-human polyclonal IgG. J Nucl Biol Med. 1991 Jan-Mar; 35(1):4-9.
View in: PubMed

Adelstein SJ, Kassis AI, Baranowska-Kortylewicz J, Van den Abbeele AD, Mariani G, Ito S. . Potential for tumor therapy with iodine-125 labeled immunoglobulins. Nucl Medicine Biol. 1991; 18:43-4.
View in: PubMed

Adelstein SJ, Kassis AI, Baranowska-Kortylewicz J, van den Abbeele AD, Mariani G, Ito S. Potential for tumor therapy with iodine-125 labeled immunoglobulins. Int J Rad Appl Instrum B. 1991; 18(1):43-4.
View in: PubMed

Janicek MJ, Van den Abbeele AD, Hollenberg NK, Kassis AI, Holman BL, Tumeh SS. Platelet activation and aggregation after endothelial injury. Assessment with indium-111-labeled platelets and angiography. Invest Radiol. 1990 Sep; 25(9):988-93.
View in: PubMed

Kassis AI, Van den Abbeele AD, Wen PY, Baranowska-Kortylewicz J, Aaronson RA, DeSisto WC, Lampson LA, Black PM, Adelstein SJ. Specific uptake of the auger electron-emitting thymidine analogue 5-[123I/125I]iodo-2'-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans. Cancer Res. 1990 Aug 15; 50(16):5199-203.
View in: PubMed

Makrigiorgos GM, Ito S, Baranowska-Kortylewicz J, Vinter DW, Iqbal A, Van den Abbeele AD, Adelstein SJ, Kassis AI. Inhomogeneous deposition of radiopharmaceuticals at the cellular level: experimental evidence and dosimetric implications. J Nucl Med. 1990 Aug; 31(8):1358-63.
View in: PubMed

Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res. 1990 Apr 01; 50(7):2198-202.
View in: PubMed

van den Abbeele AD, Aaronson RA, Taube RA, Adelstein SJ, Kassis AI. Preadsorption of radiolabeled monoclonal antibodies to liver and spleen tissues leads to higher tumor-to-normal-tissue ratios. J Nucl Med Allied Sci. 1990 Apr-Jun; 34(2):94-102.
View in: PubMed

Van den Abbeele AD, Wen PYC, Aaronson RA, Makrigiorgos GM, Morris JH, Baranowska-Kortylewicz J, Lampson LA, Black PM, Adelstein SJ, Kassis Al. Autoradiographic validation of 5-[123/125/] iodo-2'-deoxyurdine as a diagnostic and therapeutic agent for brain tumors. J Nucl Med,. 1990; 31(766).
View in: PubMed

Makrigiorgos GM, Baranowska-Kortylewicz J, Van den Abbeele AD, Ito S, Vinter DW, Adelstein SJ, Kassis AI. Microscopic spatial inhomogeneity of radiopharmaceutical deposition in mammalian tissues: dosimetry at the cellular level and comparison with conventional dosimetry. Radiat Prot Dosim. 1990; 31:319-24..
View in: PubMed

Muto MG, Lepisto EM, Van den Abbeele AD, Knapp RC, Kassis AI. Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125. Am J Obstet Gynecol. 1989 Nov; 161(5):1206-12.
View in: PubMed

Kinsey BM, Van den Abbeele AD, Adelstein SJ, Kassis AI. Absence of preferential uptake of [125I]iododihydrorhodamine 123 by four human tumor xenografts. Cancer Res. 1989 Nov 01; 49(21):5986-8.
View in: PubMed

Weadock KS, Anderson LL, Van den Abbeele AD, Makrigiorgos G, Kassis Al. Radiolabeled biodegradable membranes for radioimmunotherapy. Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA. 1989; 98.
View in: PubMed

Weadock KS, Anderson LL, Van den Abbeele AD, Maktrigiorgos G, Kassis AI. . Radiolabeled biodegradable membranes for radioimmunotherapy. Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer. 1989; 98.
View in: PubMed

Borras-Boneu G, Knapp RC, Van den Abbeele AD, Kassis Al. Biodistribution of radiolabeled MOv18 in nude mice bearing ovarian cancer xenografts. Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA. 1989; 97.
View in: PubMed

Mariani G, Van den Abbeele AD, Venkateshan CN, Kaldany A, Ito S, Adelstein SJ, Kassis AL. Internalization of monoclonal 3G5-IgM by a rat insulinoma cell line. Nuclear medicine: trends and possibilities in nuclear medicine. 1989; 602-605.
View in: PubMed

Mariani G, Abbeele AD, Venkateshan CN, Kaldany A, Ito S, Adelstein SJ, Kassis AI. Monoclonal antibody internalization by tumor cells: an experimental model for potential radioimmunotherapy applications. Int J Rad Appl Instrum B. 1989; 16(2):147-50.
View in: PubMed

Van den Abbeele AD, Aaronson RA, Adelstein SJ, Kassis AI. Does the in vitro testing of the immunoreactivity of an antibody reflect its in vivo behavior? J Nucl Med Allied Sci. 1988 Oct-Dec; 32(4):260-7.
View in: PubMed

Layne WW, Kassis AI, Van den Abbeele A, Kinsey BM, Adelstein SJ. HPLC analysis of the dissociation and recombination of rabbit immunoglobulin G. J Immunol Methods. 1987 Feb 11; 96(2):195-9.
View in: PubMed

Engelhardt B, Sandberg K, Bratton D, Van den Abbeele A, Grogaard J, Hellerqvist C, Sundell H. The role of granulocytes in the pulmonary response to group B streptococcal toxin in young lambs. Pediatr Res. 1987 Feb; 21(2):159-65.
View in: PubMed

Van den Abbeele AD, Treves ST, Lebowitz RL, Bauer S, Davis RT, Retik A, Colodny A. Vesicoureteral reflux in asymptomatic siblings of patients with known reflux: radionuclide cystography. Pediatrics. 1987 Jan; 79(1):147-53.
View in: PubMed

Van den Abbeele AD, Hardoff R, Royal HD, Kolodny GM. Bone metastases in Zollinger-Ellison syndrome: detection by bone scintigraphy. Clin Nucl Med. 1987; 12:954-5..
View in: PubMed

Van den Abbeele A, Parker JA, Royal HD. Parathyroid scintigraphy. Division of Nuclear Medicine, Beth Israel Hospital, Harvard Medical School. 1986; 7(2).
View in: PubMed

Grogaard J, Van den Abbeele A, Sundell H. Effect of alcohol on apnea reflexes in young lambs. J Appl Physiol (1985). 1985 Aug; 59(2):420-5.
View in: PubMed

Sundell HW, Rojas J, Grogaard J, Mohan P, Engelhardt B, Van den Abbeele A, Harris TR, Brigham KL. Lung lymph studies in newborn lambs with hyaline membrane disease. The physiological development of the fetus and newborn. 1985; 331-335.
View in: PubMed

Van den Abbeele A, Solorzano C, Jones AG, Beardsley DS, Treves S, Davison A. Leukocyte labeling with isonitrile complexes of technetium-99m. J Nucl Med. 1985; 26:P131.
View in: PubMed

Top